The Malaysian Reserve

Oral Presentation: Five Hematologic Malignancies Studies by Leads Biolabs to Be Featured at ASH 2025

Leads Biolabs (Stock Code: 9887.HK) today announced that five research abstracts from its hematological oncology portfolio—includin ...

Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025

Developed by Ascentage Pharma, olverembatinib is the first China-approved third-generation BCR-ABL inhibitor, currently being jointly commercialized in China by Ascentage Pharma and Innovent Biologics ...

Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025

Developed by Ascentage Pharma, lisaftoclax is an orally available Bcl-2 inhibitor. Early data from the studies have demonstrated effects on hematologic malignancies and solid tumors. Lisaftoclax is ...

Capital B publishes its results for the first half of 2025

Group EBITDA of (€634k), including costs related to the Bitcoin Treasury Company strategy of €1.2m* Adjusted EBITDA of the Group's historical operating entities IORGA & TRIMANE ...

Why IT leaders should pay attention to Canva’s ‘imagination era’ strategy

For technology teams, Canva’s approach offers important lessons, including a commitment to openness. “There are so many ...
The Park Record

Tourism Fall Forum returns with new interactive format to kick off the winter season

On Nov. 6, from 11:30 a.m. to 1:30 p.m. at the Stein Eriksen Lodge, the 2025 Tourism Fall Forum will bring together resort leaders, business owners and residents for a new version of the longstanding ...